These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 25232827

  • 1. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
    Nassar FJ, El Sabban M, Zgheib NK, Tfayli A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A, Calin GA, Nasr R.
    PLoS One; 2014; 9(9):e107566. PubMed ID: 25232827
    [Abstract] [Full Text] [Related]

  • 2. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
    Kalinina T, Kononchuk V, Alekseenok E, Obukhova D, Sidorov S, Strunkin D, Gulyaeva L.
    Genes (Basel); 2021 Apr 16; 12(4):. PubMed ID: 33923732
    [Abstract] [Full Text] [Related]

  • 3. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.
    PLoS One; 2014 Apr 16; 9(1):e87032. PubMed ID: 24498016
    [Abstract] [Full Text] [Related]

  • 4. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR.
    J Transl Med; 2019 Oct 03; 17(1):334. PubMed ID: 31581940
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
    Breast Cancer Res; 2009 Oct 03; 11(3):R27. PubMed ID: 19432961
    [Abstract] [Full Text] [Related]

  • 6. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
    Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.
    Mol Oncol; 2014 Jul 03; 8(5):874-83. PubMed ID: 24694649
    [Abstract] [Full Text] [Related]

  • 7. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
    Sakurai M, Masuda M, Miki Y, Hirakawa H, Suzuki T, Sasano H.
    Int J Biol Markers; 2015 May 26; 30(2):e190-9. PubMed ID: 25907662
    [Abstract] [Full Text] [Related]

  • 8. The expression and significance of five types of miRNAs in breast cancer.
    Min W, Wang B, Li J, Han J, Zhao Y, Su W, Dai Z, Wang X, Ma Q.
    Med Sci Monit Basic Res; 2014 Jul 21; 20():97-104. PubMed ID: 25047098
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
    Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN.
    Cell Cycle; 2011 Feb 01; 10(3):507-17. PubMed ID: 21270527
    [Abstract] [Full Text] [Related]

  • 10. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
    McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M.
    J Biol Chem; 2018 Jan 26; 293(4):1163-1177. PubMed ID: 29162724
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA regulation of progesterone receptor in breast cancer.
    Gilam A, Shai A, Ashkenazi I, Sarid LA, Drobot A, Bickel A, Shomron N.
    Oncotarget; 2017 Apr 18; 8(16):25963-25976. PubMed ID: 28404930
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
    Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R.
    Diagn Pathol; 2012 Mar 22; 7():31. PubMed ID: 22439831
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-10b expression in breast cancer and its clinical association.
    Zhang J, Yang J, Zhang X, Xu J, Sun Y, Zhang P.
    PLoS One; 2018 Mar 22; 13(2):e0192509. PubMed ID: 29408861
    [Abstract] [Full Text] [Related]

  • 15. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.
    Endocr Relat Cancer; 2013 Feb 22; 20(1):91-102. PubMed ID: 23183268
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
    Niedźwiecki S, Piekarski J, Szymańska B, Pawłowska Z, Jeziorski A.
    Ginekol Pol; 2018 Feb 22; 89(8):415-420. PubMed ID: 30215459
    [Abstract] [Full Text] [Related]

  • 17. MiR-4728-3p could act as a marker of HER2 status.
    Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y, Liu P.
    Cancer Biomark; 2015 Feb 22; 15(6):807-14. PubMed ID: 26406406
    [Abstract] [Full Text] [Related]

  • 18. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients.
    Hafez MM, Hassan ZK, Zekri AR, Gaber AA, Al Rejaie SS, Sayed-Ahmed MM, Al Shabanah O.
    Asian Pac J Cancer Prev; 2012 Feb 22; 13(2):591-8. PubMed ID: 22524830
    [Abstract] [Full Text] [Related]

  • 19. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    Alunni-Fabbroni M, Majunke L, Trapp EK, Tzschaschel M, Mahner S, Fasching PA, Fehm T, Schneeweiss A, Beck T, Lorenz R, Friedl TWP, Janni W, Rack B, SUCCESS Study Group.
    BMC Cancer; 2018 Feb 06; 18(1):141. PubMed ID: 29409452
    [Abstract] [Full Text] [Related]

  • 20. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C, You S, Mendoza PM, Aneja R, Sahin AA, Li X.
    Breast J; 2018 Nov 06; 24(6):889-893. PubMed ID: 30230095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.